In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor

A. Arimura; M. D. Culler; C. M. Turkelson; M. G. Luciano; C. R. Thomas; N. Obara; K. Groot; J. Rivier; W. Vale

doi:10.1016/0196-9781(83)90175-4

In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor

A. Arimura, M. D. Culler, C. M. Turkelson, M. G. Luciano, C. R. Thomas, N. Obara, K. Groot, J. Rivier, W. Vale

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

The hypophysiotropic activities of a synthetic human pancreatic growth hormone releasing factor (hpGRF) with 40 residues was examined in vitro using rat pituitary halves. At concentrations from 10^-10 M to 10^-7 M the peptide stimulated GH release in a dose-dependent manner with the ED₅₀ being 1.2×10^-9 M. The concentration of 10^-10 M hpGRF is comparable to the basal hypophyseal portal blood levels of other known hypothalamic hypophysiotropic hormones. However, GH release was enhanced three-fold by concentration as low as 10^-12 M, though no dose-response relationship was observed up to 10^-10 M. Thus, this peptide not only stimulates the release of GH in a dose-dependent manner, but at lower concentrations also maintains elevated GH levels. The release of ACTH, β-endorphin, LH, and FSH was not affected by hpGRF at any of the concentrations tested. At hpGRF concentrations less than 10^-7 M, the release of TSH and PRL were unaffected. However, at 10^-6 M, TSH release was enhanced about 2.5 fold and prolactin release was elevated slightly.

Original language	English (US)
Pages (from-to)	107-110
Number of pages	4
Journal	Peptides
Volume	4
Issue number	1
DOIs	https://doi.org/10.1016/0196-9781(83)90175-4
State	Published - 1983
Externally published	Yes

Keywords

GH Pituitary hormones
Growth hormone releasing factor (GRF)
In vitro test
Rat pituitary

ASJC Scopus subject areas

Biochemistry
Physiology
Endocrinology
Cellular and Molecular Neuroscience

Access to Document

10.1016/0196-9781(83)90175-4

Cite this

@article{7e50778a2045467e99e463adb2e3821f,

title = "In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor",

abstract = "The hypophysiotropic activities of a synthetic human pancreatic growth hormone releasing factor (hpGRF) with 40 residues was examined in vitro using rat pituitary halves. At concentrations from 10-10 M to 10-7 M the peptide stimulated GH release in a dose-dependent manner with the ED50 being 1.2×10-9 M. The concentration of 10-10 M hpGRF is comparable to the basal hypophyseal portal blood levels of other known hypothalamic hypophysiotropic hormones. However, GH release was enhanced three-fold by concentration as low as 10-12 M, though no dose-response relationship was observed up to 10-10 M. Thus, this peptide not only stimulates the release of GH in a dose-dependent manner, but at lower concentrations also maintains elevated GH levels. The release of ACTH, β-endorphin, LH, and FSH was not affected by hpGRF at any of the concentrations tested. At hpGRF concentrations less than 10-7 M, the release of TSH and PRL were unaffected. However, at 10-6 M, TSH release was enhanced about 2.5 fold and prolactin release was elevated slightly.",

keywords = "GH Pituitary hormones, Growth hormone releasing factor (GRF), In vitro test, Rat pituitary",

author = "A. Arimura and Culler, {M. D.} and Turkelson, {C. M.} and Luciano, {M. G.} and Thomas, {C. R.} and N. Obara and K. Groot and J. Rivier and W. Vale",

note = "Funding Information: Forty residue hpGRF with C-terminal carbohydroxy group was synthesized by solid phase methods \[14\]a nd purified using high performance liquid chromatography 1This study was supported in part by NIH research grants AM 09094, HD 14761, and AM 26741, and U.S.-Japan Collaborative Medical Research Program at Tulane University.",

year = "1983",

doi = "10.1016/0196-9781(83)90175-4",

language = "English (US)",

volume = "4",

pages = "107--110",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor

AU - Arimura, A.

AU - Culler, M. D.

AU - Turkelson, C. M.

AU - Luciano, M. G.

AU - Thomas, C. R.

AU - Obara, N.

AU - Groot, K.

AU - Rivier, J.

AU - Vale, W.

N1 - Funding Information: Forty residue hpGRF with C-terminal carbohydroxy group was synthesized by solid phase methods \[14\]a nd purified using high performance liquid chromatography 1This study was supported in part by NIH research grants AM 09094, HD 14761, and AM 26741, and U.S.-Japan Collaborative Medical Research Program at Tulane University.

PY - 1983

Y1 - 1983

N2 - The hypophysiotropic activities of a synthetic human pancreatic growth hormone releasing factor (hpGRF) with 40 residues was examined in vitro using rat pituitary halves. At concentrations from 10-10 M to 10-7 M the peptide stimulated GH release in a dose-dependent manner with the ED50 being 1.2×10-9 M. The concentration of 10-10 M hpGRF is comparable to the basal hypophyseal portal blood levels of other known hypothalamic hypophysiotropic hormones. However, GH release was enhanced three-fold by concentration as low as 10-12 M, though no dose-response relationship was observed up to 10-10 M. Thus, this peptide not only stimulates the release of GH in a dose-dependent manner, but at lower concentrations also maintains elevated GH levels. The release of ACTH, β-endorphin, LH, and FSH was not affected by hpGRF at any of the concentrations tested. At hpGRF concentrations less than 10-7 M, the release of TSH and PRL were unaffected. However, at 10-6 M, TSH release was enhanced about 2.5 fold and prolactin release was elevated slightly.

AB - The hypophysiotropic activities of a synthetic human pancreatic growth hormone releasing factor (hpGRF) with 40 residues was examined in vitro using rat pituitary halves. At concentrations from 10-10 M to 10-7 M the peptide stimulated GH release in a dose-dependent manner with the ED50 being 1.2×10-9 M. The concentration of 10-10 M hpGRF is comparable to the basal hypophyseal portal blood levels of other known hypothalamic hypophysiotropic hormones. However, GH release was enhanced three-fold by concentration as low as 10-12 M, though no dose-response relationship was observed up to 10-10 M. Thus, this peptide not only stimulates the release of GH in a dose-dependent manner, but at lower concentrations also maintains elevated GH levels. The release of ACTH, β-endorphin, LH, and FSH was not affected by hpGRF at any of the concentrations tested. At hpGRF concentrations less than 10-7 M, the release of TSH and PRL were unaffected. However, at 10-6 M, TSH release was enhanced about 2.5 fold and prolactin release was elevated slightly.

KW - GH Pituitary hormones

KW - Growth hormone releasing factor (GRF)

KW - In vitro test

KW - Rat pituitary

UR - http://www.scopus.com/inward/record.url?scp=0020959781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020959781&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(83)90175-4

DO - 10.1016/0196-9781(83)90175-4

M3 - Article

C2 - 6408622

AN - SCOPUS:0020959781

SN - 0196-9781

VL - 4

SP - 107

EP - 110

JO - Peptides

JF - Peptides

IS - 1

ER -

In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this